Prognostic Factors and Recurrence Patterns in Esophageal Cancer

Esophageal cancer remains a formidable malignancy with high rates of recurrence despite advances in multimodal treatment. Prognostic factors influencing recurrence and survival encompass tumour stage, histological subtype, lymphovascular invasion and nodal involvement, as well as patient performance status. Patterns of relapse are broadly classified into locoregional recurrence—manifesting at the surgical bed or regional lymph nodes—and distant metastases, including hepatic, pulmonary and bone spread. Early recurrence, defined within twelve months of curative surgery, portends a particularly poor prognosis. The burden and distribution of metastatic sites have been linked to post-recurrence survival, with solitary or oligometastatic disease associated with better outcomes when amenable to aggressive therapy. The role of salvage treatment, encompassing chemoradiation, metastasectomy and stereotactic radiotherapy, varies according to recurrence pattern and patient fitness. Recent efforts to integrate predictive modelling and consensus definitions have further refined risk stratification, guiding individualised follow-up and therapeutic approaches. Across diverse healthcare settings, embracing both technological innovation and clinical consensus remains pivotal to improving long-term outcomes and quality of life for patients with recurrent esophageal cancer.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Prognostic Factors and Recurrence Patterns in Esophageal Cancer publication trend

The graph below shows the total number of articles in prognostic factors and recurrence patterns in esophageal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Locoregional recurrence: Return of cancer at the primary site or regional lymph nodes following initial treatment.

Distant recurrence: Metastatic spread to organs or lymph nodes beyond the local and regional field.

Oligometastasis: State of limited metastatic disease, typically defined as up to three lesions in a single organ or one extra-regional lymph node station, potentially amenable to local therapies.

Lymphovascular invasion: Presence of cancer cells within lymphatic or blood vessels detected on histopathology.

Progression-free survival: Interval during which a patient remains free from radiological or clinical disease progression following treatment.

Neoadjuvant therapy: Treatment administered before the primary therapy, often to reduce tumour burden prior to surgery.

References

1. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. European Journal of Cancer (2023).
2. Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent. Annals of Surgical Oncology (2015).
3. Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. BMC Cancer (2020).
4. Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer: a Japanese multi-institutional study of 237 patients. Radiation Oncology (2017).
5. Machine learning to predict early recurrence after oesophageal cancer surgery. British Journal of Surgery (2020).